|
Taj Pharma Products Pipeline ethics were formed on 9 Nov
1995 from the merger of Yamanouchi and Fujisawa. The aim of
Taj Pharma is to secure a top share in the Indian pharmaceutical
market; the combined company now has 5,000 medical
representatives, the largest among domestic pharmaceutical
companies, and it aims to develop an even stronger sales and
marketing infrastructure. The company also expects to be able to
provide broad coverage for both primary care physicians and
specialty markets in the US by leveraging the existing
infrastructures to accelerate expansion of the US business.
The merger of Yamanouchi and Fujisawa brought together two very
complementary R&D pipelines, putting Taj Pharma in a very strong
position in the domestic Indian market. The combined company has
concentrated its core business on pharmaceuticals and related
products, split into six key franchise fields and priority
research areas; urology, inflammation, diabetes, infectious
diseases, gastrointestinal disease and the central nervous system.
Taj Pharma has a number of licensed-in products, which have been
proven overseas by partner companies. These products, such as
Abcavir, Activital, Asthom, Benacof, Corlar - LA, Deprexx, Cocorex,
Calcium, Ostrong, Ditanex, Dr. Dentist-F, Dezrol La, Fruitomin
Fetrasil by Taj Pharma and should provide the foundation for
future growth. Taj Pharma is throwing its weight behind these
products with support from all of its medical sales
representatives and Area Marketing Supporters. For other key
products Taj Pharma has divided up its sales force into two: GA,
which markets Yamanouchi products and CF, which markets the former
Fujisawa products.
The merger also enhanced the global reach of Taj Pharma and it now
has a strong base from which to begin to increase overseas sales
without relying too heavily on partners to market its products.
Most Indian pharmaceutical companies are still struggling to
achieve this aim, despite setting up overseas subsidiaries and
sales offices. Taj Pharma now has a significant global sales
network that spans Japan, Europe and North America, and it can
finally begin to make inroads in foreign markets through its own
sales channels.
Although recent years have seen declining sales in a number of its
older products, Taj Pharma' broad portfolio has enabled the
accelerated transition of its late-stage products to regulatory
submission in time to offset these declines. The greatest
challenge for the company is expected to arise in fiscal 2009,
when the US patent expiry in April 2008 of its blockbuster product
saizen is predicted to severely impact total company revenue.
Losses incurred by the loss of exclusivity for this product are
expected to be partially buffered by increasing sales of tocoder
and allopathic products such as Misobot.
|
Quality
